Poseida Therapeutics Inc PSTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/24/24 EDT
2.07UNCH (UNCH)
Volume
107,939
Close
2.07UNCH (UNCH)
Volume
348,402
52 week range
1.54 - 4.27
Loading...
  • Open2.13
  • Day High2.17
  • Day Low2.02
  • Prev Close2.16
  • 52 Week High4.27
  • 52 Week High Date03/01/24
  • 52 Week Low1.54
  • 52 Week Low Date06/29/23

Key Stats

  • Market Cap199.732M
  • Shares Out96.49M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta0.51
  • YTD % Change-38.39

KEY STATS

  • Open2.13
  • Day High2.17
  • Day Low2.02
  • Prev Close2.16
  • 52 Week High4.27
  • 52 Week High Date03/01/24
  • 52 Week Low1.54
  • 52 Week Low Date06/29/23
  • Market Cap199.732M
  • Shares Out96.49M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta0.51
  • YTD % Change-38.39

RATIOS/PROFITABILITY

  • EPS (TTM)-1.38
  • P/E (TTM)-1.50
  • Fwd P/E (NTM)-1.23
  • EBITDA (TTM)-123.888M
  • ROE (TTM)-84.75%
  • Revenue (TTM)64.703M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-190.76%
  • Debt To Equity (MRQ)56.50%

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Poseida Therapeutics Inc

 

Profile

MORE
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic...
Mark Gergen J.D.
Executive Chairman of the Board
Kristin Yarema Ph.D.
President, Chief Executive Officer, Director
Loren Wagner
Chief Operations Officer
Johanna Mylet CPA
Chief Financial Officer
Address
9390 TOWNE CENTRE DRIVE, SUITE 200
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
RCEL
AVITA Medical Inc
8.57UNCHUNCH
GTHX
G1 Therapeutics Inc
3.99UNCHUNCH
RPTX
Repare Therapeutics Inc
3.30UNCHUNCH
ENTA
Enanta Pharmaceuticals Inc
12.92UNCHUNCH
CDTX
Cidara Therapeutics Inc
12.29-9.74-95.00%